|1.||Diederich, Marc: 2 articles (11/2014 - 03/2009)|
|2.||Morceau, Franck: 2 articles (11/2014 - 03/2009)|
|3.||Dicato, Mario: 2 articles (11/2014 - 03/2009)|
|4.||Platanias, Leonidas C: 1 article (11/2015)|
|5.||Goussetis, Dennis J: 1 article (11/2015)|
|6.||Gaigneaux, Anthoula: 1 article (11/2014)|
|7.||Trécul, Anne: 1 article (11/2014)|
|8.||Schnekenburger, Michael: 1 article (11/2014)|
|9.||Zhou, Wenjin: 1 article (11/2014)|
|10.||Zheng, Cuiping: 1 article (11/2014)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
01/01/1978 - "A phase II trial of which preliminary results are available for 22 patients indicates that aclacinomycin applied in a continuous modality induced complete and partial remission in four of nine patients with acute lymphoid leukaemia that was resistant to all previously available drugs, and in four of eight patients with stage V lymphosarcoma (leukaemic). "
01/01/1978 - "Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. "
01/01/1980 - "Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma."
04/01/1986 - "Nineteen patients with refractory non-Hodgkin's lymphoma were treated with a combination of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (150-200 mg/m2), aclacinomycin (15 mg/m2), etoposide (70 mg/m2 i.v. or 100 mg/m2 p.o) and prednisolone (20 mg/m2) (ABEP regimen). "
01/01/1989 - "Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone."
|2.||Malignant Pleural Effusion
07/01/1984 - "We posit that the local instillation of aclacinomycin is indicated in the management of malignant pleural effusion."
08/01/1983 - "[Aclacinomycin; benefits for the treatment of malignant pleural effusion]."
07/01/1984 - "[Efficacy of intrapleural treatment with aclacinomycin combined with closed tube thoracostomy for malignant pleural effusion]."
07/01/1984 - "Intrapleural treatment with aclacinomycin combined with closed tube thoracostomy was used in 7 patients with malignant pleural effusion. "
|3.||Lewis Lung Carcinoma
01/01/1992 - "The results showed that siwenmycin was effective against P388, K562, HeLa and HEp-2 tumor cell lines in vitro, and significantly inhibited the growth of the Lewis lung carcinoma cell line in vivo. "
01/01/1992 - "A novel anthracycline antibiotic, siwenmycin, isolated from the culture of Streptomyces galilaeus var. siwenesis, was examined for its antitumor activities against P388, K562, B16-F10, HeLa, HEp-2 and Lewis lung carcinoma cell lines. "
01/01/1992 - "Siwenmycin could also suppress spontaneous and artificial pulmonary metastases of B16-F10 and Lewis lung carcinoma cell lines in C57BL/6 mice. "
01/01/1992 - "The inhibitory effect of siwenmycin on spontaneous pulmonary metastasis of Lewis lung carcinoma in C57BL/6 mice was even stronger than that of adriamycin (ADM), which is, at present, commonly used in clinical practice. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1984 - "Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia."
05/01/1983 - "We analysed the effects of three different regimens for first induction therapy with 50 cases of acute nonlymphocytic leukemia in adults and reported the results of combination therapy including aclacinomycin for reinduction therapy. "
11/01/2015 - "Synergism between arsenic trioxide and aclacinomycin in acute myeloid leukemia."
01/01/1989 - "Nine patients with acute non lymphoblastic leukaemia (ANLL) were treated with Aclacinomycin in the doses of 20 mg/m2/day x 7 days in 30' lasting intravenous infusion and Cytosin arabinosid 100 mg/m2/day x 7 days in continuous infusion as well as control group consisted of 30 healthy people were examined by means of 24 hrs Holter ECG monitoring and ultrasonocardiography (UCG) to evaluate the influence of Aclacinomycin A (Aclaplastin - Behring) on cardiac rhythm and function. "
12/01/2012 - "Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia."
01/01/1986 - "Enhancement of NK-cell activity in normal and tumor-bearing mice after administration of aclacinomycin."
01/01/1986 - "Aclacinomycin (ACM) a new cytotoxic antibiotic employed in cancer chemotherapy, can either enhance or inhibit the NK-cell activity of the immune system, depending on the dose administered. "
06/01/2004 - "Combination of aclacinomycin with MMP inhibitors could have therapeutic potential in preventing tumor metastasis."
01/01/1983 - "[Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors]."
01/01/1995 - "Aclacinomycin (ACR) is an anthracycline anticancer drug that shows marked effects in Adriamycin (ADM)-resistant tumors. "
|1.||RNA (Ribonucleic Acid)
|2.||Etoposide (VP 16)
|3.||Anti-Bacterial Agents (Antibiotics)
|5.||Sodium Chloride (Saline Solution)
|6.||Proteins (Proteins, Gene)
|3.||Drug Therapy (Chemotherapy)